Edition:
United States

ImmunoGen Inc (IMGN.OQ)

IMGN.OQ on NASDAQ Stock Exchange Global Select Market

12.15USD
22 Jun 2018
Change (% chg)

$0.47 (+4.02%)
Prev Close
$11.68
Open
$11.64
Day's High
$12.17
Day's Low
$11.40
Volume
4,772,383
Avg. Vol
795,821
52-wk High
$13.41
52-wk Low
$4.81

Chart for

About

ImmunoGen, Inc. is a clinical-stage biotechnology company that develops targeted cancer therapeutics using its antibody-drug conjugate (ADC) technology. An ADC with the Company's technology comprises an antibody that binds to a target found on tumor cells conjugated to one of its anti-cancer agents as a payload to kill the tumor... (more)

Overall

Beta: 2.11
Market Cap(Mil.): $1,782.69
Shares Outstanding(Mil.): 146.72
Dividend: --
Yield (%): --

Financials

  IMGN.OQ Industry Sector
P/E (TTM): -- 248.83 34.14
EPS (TTM): -1.11 -- --
ROI: -72.91 -5.25 13.10
ROE: -- -6.83 15.09

BRIEF-Immunogen Announces Positive Findings From Forward 2 Study Of Mirvetuximab Soravtansine Combination Regimens

* IMMUNOGEN ANNOUNCES POSITIVE FINDINGS FROM THE FORWARD II STUDY OF MIRVETUXIMAB SORAVTANSINE COMBINATION REGIMENS WITH AVASTIN® AND CARBOPLATIN IN OVARIAN CANCER

May 16 2018

BRIEF-ImmunoGen Reports Q1 Loss Per Share $0.30

* IMMUNOGEN REPORTS RECENT PROGRESS AND FIRST QUARTER 2018 OPERATING RESULTS

May 04 2018

BRIEF-Immunogen Completes Interim Analysis For Forward I Phase 3 Trial Of Mirvetuximab Soravtansine

* IMMUNOGEN ANNOUNCES SUCCESSFUL COMPLETION OF INTERIM ANALYSIS FOR FORWARD I PHASE 3 TRIAL OF MIRVETUXIMAB SORAVTANSINE IN PLATINUM-RESISTANT OVARIAN CANCER

Apr 26 2018

BRIEF-Immunogen Inc Files For Potential Mixed Shelf Offering‍​

* IMMUNOGEN INC FILES FOR POTENTIAL MIXED SHELF OFFERING; SIZE NOT DISCLOSED - SEC FILING‍​ Source text (http://bit.ly/2DablVK) Further company coverage:

Mar 07 2018

BRIEF-Immunogen Inc Reports Qtrly Net Loss Per Common Share, Basic And Diluted Of $0.11‍​

* IMMUNOGEN REPORTS PIPELINE PROGRESS AND 2017 OPERATING RESULTS

Feb 09 2018

BRIEF-Immunogen Says On Jan 8, Co Disclosed It Expects To Report That As Of Dec 31, 2017 It Had Cash And Cash Equivalents Of About $267.1 Mln

* IMMUNOGEN SAYS ON JAN 8, CO DISCLOSED IT EXPECTS TO REPORT THAT AS OF DEC 31, 2017 IT HAD CASH AND CASH EQUIVALENTS OF ABOUT $267.1 MILLION - SEC FILING Source text (http://bit.ly/2CRXR5Q) Further company coverage:

Jan 08 2018

BRIEF-ImmunoGen Announces First Patient Dosed In Phase 1 Study Of IMGN632 For Hematological Malignancies

* IMMUNOGEN ANNOUNCES FIRST PATIENT DOSED IN PHASE 1 STUDY OF IMGN632 FOR HEMATOLOGICAL MALIGNANCIES Source text for Eikon: Further company coverage:

Jan 04 2018

Competitors

Earnings vs. Estimates